Completed PHASE3 INTERVENTIONAL 2-arm NCT04340128

Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)

Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL)

Sponsor: Kerman University of Medical Sciences

Conditions Cutaneous Leishmaniasis

Interventions Meglumine antimoniate

Updated 2 times since 2024 Last updated: Apr 6, 2020 Started: May 31, 2007 Primary completion: Oct 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Cutaneous Leishmaniasis, this trial is completed. The trial is conducted by Kerman University of Medical Sciences and has accumulated 2 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kerman University of Medical Sciences
Mashad University of Medical Sciences
Tehran University of Medical Sciences

Data source: Tehran University of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tehran, Iran